Mainz Biomed/MYNZ

$0.92

1.76%
-
1D1W1MYTD1YMAX

About Mainz Biomed

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Ticker

MYNZ

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Guido Baechler

Employees

65

Headquarters

Mainz, Germany

Mainz Biomed Metrics

BasicAdvanced
$20.38M
Market cap
-
P/E ratio
-$1.67
EPS
-
Beta
-
Dividend rate
$20.38M
$6.00
$0.85
84.19K
0.972
0.906
35.877
196.681
-32.91%
-147.52%
-303.2%
-237.21%
22.76
6.066
21.97%

What the Analysts think about Mainz Biomed

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 2 analysts.
443.48% upside
High $8.00
Low $2.00
$0.92
Current price
$5.00
Average price target

Mainz Biomed Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,550% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$200K
100%
Net income
$-5.1M
-17.74%
Profit margin
-2,550%
-58.87%

Mainz Biomed Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 24.21%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.56
-$0.39
-$0.24
-
Expected
-$0.42
-$0.47
-$0.32
-$0.25
Surprise
33.33%
-17.61%
-24.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Mainz Biomed stock?

Mainz Biomed (MYNZ) has a market cap of $20.38M as of April 20, 2024.

What is the P/E ratio for Mainz Biomed stock?

The price to earnings (P/E) ratio for Mainz Biomed (MYNZ) stock is 0 as of April 20, 2024.

Does Mainz Biomed stock pay dividends?

No, Mainz Biomed (MYNZ) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Mainz Biomed dividend payment date?

Mainz Biomed (MYNZ) stock does not pay dividends to its shareholders.

What is the beta indicator for Mainz Biomed?

Mainz Biomed (MYNZ) does not currently have a Beta indicator.

What is the Mainz Biomed stock price target?

The target price for Mainz Biomed (MYNZ) stock is $5, which is 449.45% above the current price of $0.91. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Mainz Biomed stock

Buy or sell Mainz Biomed stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing